Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy

医学 Blinatumoab公司 细胞因子释放综合征 嵌合抗原受体 内科学 耐火材料(行星科学) 回顾性队列研究 儿科 肿瘤科 免疫疗法 抗体 免疫学 CD19 癌症 天体生物学 物理
作者
Khushnuma Mullanfiroze,Giorgio Ottaviano,Avijeet Kumar Mishra,Maria Gabelli,Arina Lazareva,Saskia Burridge,Susan Farish,Jan Chu,Kirsty Sharplin,David I. Marks,Maeve O’Reilly,Emma Nicholson,Kelly Watts,Denise Bonney,Danny Cheng,Jack Bartram,Sujith Samarasinghe,Vesna Pavasovic,Anupama Rao,Philip Ancliffe,Ajay Vora,Giovanna Lucchini,Robert Chiesa,Paul Veys,Kanchan Rao,Persis Amrolia,Sara Ghorashian
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 1743-1743 被引量:6
标识
DOI:10.1182/blood-2021-148820
摘要

Abstract Introduction: Immunotherapies like Inotuzumab ozogamicin (InO), Blinatumomab and Chimeric antigen receptor T cell therapy (CAR-T) have revolutionized outcomes in patients with Relapse/Refractory Acute Lymphoblastic Leukaemia (R/R ALL) with event free survival (EFS) of 50% at 1 year (Maude et al. 2018). Optimal phasing of these agents has not been clearly defined and depends on antigen expression on blasts, CNS status, T cell number and prior disease response. InO, a CD22 targeting antibody-drug conjugate has proven efficacy in adults (Kantarjian et al., 2016) and children as a bridge to allogeneic stem cell transplantation (allo-SCT) with a favourable toxicity profile (Brivio et al. 2021). However, outcomes following the use of InO prior to CAR-T therapy are still not established. This study provides a retrospective analysis of children and young adults who received InO as part of pre-CAR-T management (before leucapheresis or as bridging therapy to CAR-T infusion). Methods: Patients aged 0-25years with R/R ALL were eligible for the study if they received InO pre-CAR-T therapy. Retrospective data collection was performed using a standardised form from CAR-T centres in the UK. Response to CAR-T therapy and/or relapse was evaluated at 1, 3, 6, 12 months or at last follow-up. Results were compared to a control cohort of R/R ALL patients treated with tisagenlecleucel but without preceding InO, over a contemporaneous period, at the largest paediatric CAR-T centre in the UK. Results: Fourteen patients from 5 paediatric and young adult centres in the UK received InO after screening for CAR-T therapy. InO was used pre-leucapheresis, as bridging and for both in 2, 11 and 1 respectively. Two were excluded from outcome analysis (1 adolescent with Trisomy 21 and transfusion induced hepatic siderosis died due to VOD while awaiting CAR-T production and 1 failed CAR-T manufacture despite achieving an adequate T cell harvest as per manufacturer guidance). Twelve (85%) patients were able to receive CAR-T infusion at a median of 1 month (range 0.7-5.6 months) from first InO dose. InO was well tolerated with 21% developing febrile neutropenia and grade 4 cytopenias. Use of InO pre-leucapheresis led to successful manufacture of CAR-T cells in 2/3 (66%). InO group was compared with 27 children who received CAR-T without preceding InO over the same time period. Table 1 summarises patient and CAR-T characteristics of the two groups which were comparable. Median follow-up of the InO and non-InO groups was 10 months (range 2.8- 30.1 months). In the InO group(n=12), 3 (25%) remained leukemia free at last follow up. Nine patients (75%) relapsed. All relapses occurred within 6 months from CAR-T infusion. Seven (58%) of those who relapsed died at a median of 7.8 months post CAR-T infusion and 2 (16.6%) were salvaged with further therapy. Subsequent therapy (alternate CAR-T and/or allo-SCT) was carried out in 4/12 (33%) patients in the InO group and in 5/27 (18.5%) in the non-InO group (p= 0.2). EFS was significantly higher in the non-InO group (53% vs 12%, p=0.0009), as was OS (86% vs 13%, p=0.004) (Figure 1). Conclusion: This study provides a direct comparison between two contemporaneously treated cohorts with R/R ALL receiving CAR-T therapy. InO prior to CAR T cell therapy was well tolerated despite the cohort being heavily pre-treated except for one patient who developed fatal VOD prior to CAR T cell infusion. InO was given for disease debulking, rather than to achieve MRD negativity and hence majority of the cohort (75%) received only 1 dose of InO in bridging rather than the usual schedule of three doses weekly per cycle. Outcomes for the non-InO group were comparable to those treated on the ELIANA study but the OS of the InO group was significantly lower (13% vs 86% p= 0.004). Potential reasons include an impact of InO on function of CAR-T cells in vivo or a deleterious effect of InO on the B cell compartment such that CAR-T cells prove less effective. Due to the retrospective nature of the study, it is possible there was an inherent bias to use InO in patients with more resistant disease, although the very comparable pre CAR-T bone marrow disease burden in each group suggests this was not the case. The small size of the cohorts may also have exaggerated differences in outcome. Ultimately, randomised controlled studies of InO pre-CAR-T are required before firm conclusions about its impact on outcomes post CAR-T therapy can be ascertained. Figure 1 Figure 1. Disclosures Sharplin: Kite Gilead: Honoraria; Novartis: Other: Travel Support. Nicholson: BMS/Celgene: Consultancy; Kite, a Gilead Company: Other: Conference fees, Speakers Bureau; Novartis: Consultancy, Other: Conference fees; Pfizer: Consultancy. Amrolia: ADC Therapeutics: Other: Named inventor on a patent which is being transferred to ADCT.; Autolus: Patents & Royalties. Ghorashian: Novartis: Honoraria; UCLB: Patents & Royalties.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
SYLH应助张成采纳,获得10
2秒前
2秒前
优雅夜雪发布了新的文献求助10
3秒前
4秒前
4秒前
宋坤应助清新的访冬采纳,获得10
4秒前
琅琊为刃发布了新的文献求助10
5秒前
X先生完成签到,获得积分10
5秒前
5秒前
Vizz发布了新的文献求助10
5秒前
难过冷玉发布了新的文献求助20
5秒前
9秒前
kk发布了新的文献求助10
9秒前
10秒前
深情安青应助Dann采纳,获得10
13秒前
毒盐完成签到,获得积分20
14秒前
15秒前
zz完成签到,获得积分10
16秒前
16秒前
16秒前
体贴的乐荷完成签到,获得积分10
17秒前
小郑小郑完成签到 ,获得积分10
17秒前
zu发布了新的文献求助10
17秒前
jjb完成签到,获得积分10
17秒前
十一发布了新的文献求助20
19秒前
19秒前
JamesPei应助独特冰安采纳,获得10
19秒前
yy完成签到,获得积分20
19秒前
Horizon完成签到,获得积分10
19秒前
zhangzhang发布了新的文献求助10
21秒前
slin_sjtu发布了新的文献求助10
21秒前
思源应助。。。采纳,获得10
22秒前
研友_VZG7GZ应助花花采纳,获得10
23秒前
盛乾衣发布了新的文献求助10
25秒前
Hexagram发布了新的文献求助10
25秒前
科研通AI2S应助阿俊1212采纳,获得10
26秒前
yqqqqq发布了新的文献求助10
26秒前
26秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 310
The Moiseyev Dance Company Tours America: "Wholesome" Comfort during a Cold War 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3980154
求助须知:如何正确求助?哪些是违规求助? 3524160
关于积分的说明 11220159
捐赠科研通 3261641
什么是DOI,文献DOI怎么找? 1800734
邀请新用户注册赠送积分活动 879263
科研通“疑难数据库(出版商)”最低求助积分说明 807232